| Identification | Back Directory | [Name]
Butanediamide,N1-hydroxy-2-methyl-N4-[(1S)-2-(methylamino)-2-oxo-1-phenylethyl]-3-(2-methylpropyl)-,(2S,3R)- | [CAS]
168158-16-5 | [Synonyms]
Butanediamide,N1-hydroxy-2-methyl-N4-[(1S)-2-(methylamino)-2-oxo-1-phenylethyl]-3-(2-methylpropyl)-,(2S,3R)- | [Molecular Formula]
C18H27N3O4 | [MOL File]
168158-16-5.mol | [Molecular Weight]
349.42 |
| Hazard Information | Back Directory | [Description]
KB-R7785 is a novel ADAM12 and MMP inhibitor, ameliorating cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of HB-EGF signaling, exerting its antidiabetic effect by ameliorating insulin sensitivity through the inhibition of TNF-alpha production. | [Uses]
KB-R7785 is a novel matrix metalloproteinase (MMP) inhibitor, which improves insulin sensitivity by inhibiting TNF-α production. KB-R7785 can be used for diabetes research. KB-R7785 has a protective efficacy against focal cerebral ischemia[1][2]. | [References]
[1] Morimoto Y, et al. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. Life Sci. 1997;61(8):795-803. DOI:10.1016/s0024-3205(97)00561-4
[2] Jiang X, et al. Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett. 2001 Jun 1;305(1):41-4. DOI:10.1016/s0304-3940(01)01800-6 |
|
|